Cystic Fibrosis Pipeline Review, H2 2016 - 74 Companies & 137 Drug Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2016" report to their offering.

'Cystic Fibrosis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies

Universities.

'Cystic Fibrosis - Pipeline Review, H2 2016'; Cystic Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 121 molecules are developed by Companies and remaining by the Universities/Institutes.

It also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 20, 22, 52 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 6, 6 and 1 molecules, respectively.

Key Topics Covered:

1. Introduction
2. Cystic Fibrosis Overview
3. Therapeutics Development
4. Pipeline Products for Cystic Fibrosis - Overview
5. Pipeline Products for Cystic Fibrosis - Comparative Analysis
6. Cystic Fibrosis - Therapeutics under Development by Companies
7. Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes
8. Cystic Fibrosis Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Cystic Fibrosis - Products under Development by Companies
13. Cystic Fibrosis - Products under Investigation by Universities/Institutes
14. Cystic Fibrosis - Companies Involved in Therapeutics Development

• Actelion Ltd
• Alaxia SAS
• Arch Biopartners, Inc.
• Arcturus Therapeutics, Inc.
• Aridis Pharmaceuticals LLC
• AstraZeneca Plc
• Cilian AG
• Concert Pharmaceuticals, Inc.
• CRISPR Therapeutics
• CSA Biotechnologies LLC
• Cyclacel Pharmaceuticals, Inc.
• DiscoveryBiomed, Inc.
• Editas Medicine, Inc.
• Eloxx Pharmaceuticals, Ltd.
• ID Pharma Co., Ltd.
• Immun System I.M.S. AB
• Insmed Incorporated
• Invion Limited
• Kyorin Pharmaceutical Co., Ltd.
• La Jolla Pharmaceutical Company
• Lakewood-Amedex Inc
• Lamellar Biomedical Ltd
• Laurent Pharmaceuticals Inc.
• OSE Immunotherapeutics
• Paranta Biosciences Limited
• Parion Sciences, Inc.
• Pfizer Inc.
• Progenra, Inc.
• Savara Inc.
• Shionogi & Co., Ltd.
• Shire Plc
• Synovo GmbH
• TGV-Laboratories
• The International Biotechnology Center (IBC) Generium
• Verona Pharma Plc

For more information about this report visit http://www.researchandmarkets.com/research/4d8qd3/cystic_fibrosis